Pluri Inc. - SIC # 200 -

Ticker Exchange SIC # Website Latest Ticker
PLUR Nasdaq 200 www.pluri-biotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pluri Inc.

Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments - Oct 27th, 2026 7:00 am
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine - Oct 26th, 2026 5:00 am
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company - Oct 21st, 2026 6:30 am
Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity - Oct 13th, 2026 5:00 am
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor - Aug 27th, 2026 6:00 am
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment - Aug 17th, 2026 7:00 am
Ever After Foods Acquires Fishway to Expand Integrated Food Production Technology Platform - Aug 17th, 2026 6:30 am
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK - Jul 28th, 2026 6:00 am
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% - Jul 14th, 2026 5:00 am
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - Jun 2nd, 2026 5:30 am
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - May 30th, 2026 9:46 am
Pluri Insider Ups Holding During Year - May 28th, 2026 4:56 am
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - May 1st, 2026 2:00 pm
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement - Mar 26th, 2026 6:30 am
Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent - Feb 18th, 2026 6:00 am
Pluri showcases cell expansion platform as Resbiomed program advances - Feb 9th, 2026 8:30 am
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials - Jan 22nd, 2026 7:15 am
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Dec 22nd, 2025 5:00 am